Amplia Therapeutics Ltd (ASX: ATX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Amplia Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $18.20 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 271.61 million
Earnings per share -0.022
Dividend per share N/A
Year To Date Return -13.83%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Amplia Therapeutics Ltd (ASX: ATX)
    Latest News

    A medical researcher in a white coat holds laboratory equipment and smiles.
    Share Market News

    Why the Amplia (ASX:ATX) share price is rocketing 41% higher today

    The Australian pharmaceutical company sees its share price jump after good news on a drug trial.

    Read more »

    woman in lab coat conducting testing representing biotech
    Share Market News

    Here's why the Amplia (ASX:ATX) share price is up 9% today

    The Amplia Therapeutics Ltd (ASX: ATX) share price is running 9% higher today following progress on its AM945 inhibitor. Here's…

    Read more »

    Share Market News

    Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake

    The Amplia Therapetics Ltd (ASX: ATX) share price has risen16% since Tuesday following an announcement that a former Macquarie CEO…

    Read more »

    a woman
    Share Market News

    US congressman resigns over ASX insider trading penny stock scandal

    Can you make money in penny stocks?

    Read more »

    a woman
    Share Market News

    ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)

    A US Congressman and former director of Innate Immunotherapeutics Ltd (ASX:IIL) has been arrested for conspiracy to commit securities fraud.

    Read more »

    a woman
    ⏸️ Investing

    Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter

    Cann Group Ltd (ASX:CAN) shares are one of 64 new additions to the All Ordinaries (Index:^AXAO) (ASX:XAO) this month. Here's…

    Read more »

    a woman
    ⏸️ Investing

    Were these the 3 worst shares on the ASX in 2017?

    The iSentia Group Ltd (ASX:ISD) share price was one of three that destroyed the wealth of unlucky shareholders in 2017…

    Read more »

    a woman
    ⏸️ Investing

    These are the 5 biggest losers on the All Ordinaries in the last 12 months

    The Quintis Ltd (ASX:QIN) share price is amongst the five biggest losers on the All Ordinaries (Index:^AXAO) (ASX:XAO) over the…

    Read more »

    a woman
    ⏸️ Investing

    One crucial thing to consider before investing in risky biotech shares

    Consider this before owning shares in companies like Resapp Health Ltd (ASX:RAP) and Innate Immunotherapeutics Ltd (ASX:IIL).

    Read more »

    a woman
    ⏸️ Investing

    The 3 biggest investing mistakes you can make

    Buying Commonwealth Bank of Australia (ASX:CBA) and Wesfarmers Ltd (ASX:WES) shares may sound boring, but it’s better than some alternatives.

    Read more »

    a woman
    ⏸️ Investing

    Here's how to get rich quick (and stay poor forever)

    Buying speculative stocks like Innate Immunotherapeutics Ltd (ASX:IIL) and Resapp Health Ltd (ASX:RAP) is not a reliable way to grow…

    Read more »

    a woman
    ⏸️ Investing

    Warning: Every investor should read this before buying speculative biotech companies

    You could lose your shirt investing in companies like Innate Immunotherapeutics Ltd (ASX:IIL).

    Read more »

    ATX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Amplia Therapeutics Ltd

    Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

    ATX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Jun 2024 $0.07 $0.00 0.00% 16,801 $0.07 $0.07 $0.07
    14 Jun 2024 $0.07 $0.00 0.00% 1,411 $0.07 $0.07 $0.07
    13 Jun 2024 $0.07 $0.00 0.00% 154,010 $0.07 $0.07 $0.07
    12 Jun 2024 $0.07 $0.00 0.00% 52,027 $0.07 $0.07 $0.07
    11 Jun 2024 $0.07 $0.00 0.00% 295,382 $0.07 $0.07 $0.07
    07 Jun 2024 $0.07 $0.00 0.00% 119,970 $0.07 $0.07 $0.07
    06 Jun 2024 $0.07 $0.00 0.00% 84,592 $0.07 $0.07 $0.07
    05 Jun 2024 $0.07 $0.00 0.00% 195,797 $0.08 $0.08 $0.07
    04 Jun 2024 $0.07 $0.00 0.00% 444,188 $0.07 $0.08 $0.07
    03 Jun 2024 $0.07 $0.00 0.00% 344,996 $0.07 $0.08 $0.07
    31 May 2024 $0.07 $0.00 0.00% 117,109 $0.07 $0.07 $0.07
    30 May 2024 $0.07 $0.00 0.00% 389,143 $0.07 $0.07 $0.06
    29 May 2024 $0.06 $0.00 0.00% 453,870 $0.07 $0.07 $0.06
    27 May 2024 $0.06 $0.00 0.00% 348,263 $0.07 $0.07 $0.06
    24 May 2024 $0.07 $0.00 0.00% 238,124 $0.07 $0.07 $0.06
    23 May 2024 $0.06 $0.00 0.00% 273,022 $0.06 $0.06 $0.06
    22 May 2024 $0.06 $0.00 0.00% 85,855 $0.06 $0.06 $0.06
    21 May 2024 $0.06 $0.00 0.00% 1,460,118 $0.06 $0.06 $0.06

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 May 2024 Christopher Burns Issued 616,672 $33,916
    Rights issue. As per announcement on 21-05-2024
    15 May 2024 Jane Bell Issued 671,608 $36,938
    Rights issue.
    15 May 2024 Robert Peach Issued 1,900,005 $104,500
    Rights issue.
    15 May 2024 Jane Bell Issued 138,582 $7,622
    Rights issue.
    31 Aug 2023 Robert Peach Expiry 480,000 $42,240
    Options expired.
    29 Aug 2023 Christopher Burns Issued 2,500,000 $220,000
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew John Cooke Company Secretary Oct 2013
    Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
    Dr John Lambert Chief Executive Officer Jun 2019
    Dr Lambert was appointed CEO on 24 June 2019 and Managing Director on 6 February 2020. John has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, he was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry he was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
    Dr Robert Peach Non-Executive Director Sep 2015
    Dr Peach has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industry. He was appointed as an Independent Non-Executive Director on 2nd of September 2015.
    Ms Jane Catherine Bell Non-Executive Director Apr 2021
    Ms Bell has more than 30 years' experience in leading law firms, financial services and corporate treasury operations in Melbourne, London, Toronto, San Francisco and Brisbane.
    Dr Warwick Bonner Tong Non-Executive DirectorNon-Executive Chairman May 2018
    Dr Tong is a NZ trained physician with more than 25 years' experience in the pharmaceutical and biotechnology industry. Dr Tong was appointed as a Non-Executive Director on 4th of May 2018 and Chairman on 25th May 2018.
    Dr Christopher John Burns Non Executive DirectorChief Executive OfficerManaging Director May 2018
    Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 30 years. Dr Burns was originally appointed as a Non-Executive Director on 4th May 2018 and was subsequently appointed as Chief Executive Officer and Managing Director on 5th December 2022.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 36,892,524 19.02%
    Bond Street Custodians Limited (Lam1 - D08047 A/C) 13,472,500 6.94%
    BNP Paribas Noms Pty Ltd 6,690,878 3.45%
    J P Morgan Nominees Australia Pty Limited 6,052,184 3.12%
    Citicorp Nominees Pty Limited 5,678,561 2.93%
    UBS Nominees Pty Ltd 4,024,411 2.07%
    Ctxt Pty Ltd 3,940,579 2.03%
    Elk River Holdings Pty Ltd 3,067,142 1.58%
    Warwick Tong 3,016,247 1.55%
    Christopher John Burns 2,527,798 1.30%
    Gp Securities Pty Ltd 2,412,500 1.24%
    34Th Avenue Pty Ltd (Devlin Family A/C) 2,215,237 1.14%
    Heh Entreprises Pty Ltd (Heh Entreprises Invest A/C) 2,050,000 1.06%
    Mrs Jane Catherine Jocelyn Bell + Mr Geoffrey Arthur Bell (Schooner Super Fund A/C) 2,025,474 1.04%
    Mr Andrew Podolak 1,925,000 0.99%
    Mr Anthony Hamilton Martin 1,822,539 0.94%
    Robert James Peach + Cofactor Llc 1,664,760 0.86%
    Mr Mark Sullivan 1,661,428 0.86%
    Citicorp Nominees Pty Limited (Dpsl A/C) 1,537,327 0.79%
    Swanmark Super Pty Ltd Rc (Swan Super Fund A/C) 1,500,000 0.77%

    Profile

    since

    Note